With the stock's current price at Rs 2819.60, GlaxoSmithKline Pharmaceuticals is navigating through market dynamics, ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14. The agreement includes a $1.2 billion ...

Andrew Witty is a business executive well-known for his contributions to the Pharmaceutical and health sectors.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

British pharmaceutical giant GlaxoSmithKline announced Wednesday the acquisition of a drug under development to treat a ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

UnitedHealth Group Inc. on May 13 issued an update with two items of notable news, saying that its medical costs are likely ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GlaxoSmithKline (GSK) has announced the repurchase of 783,700 of its ordinary shares as part of its ongoing buyback program, executed through Citigroup Global Markets Limited. This transaction is part ...